Federal Register / Vol. 76, No. 56 / Wednesday, March 23, 2011 / Notices 16427 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2011–N–0002] 

Risk Communication Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Risk 

Communication Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the Agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on May 5, 2011, from 8 a.m. to 

5 p.m. 

Location: Food and Drug 

Administration, 5630 Fishers Lane, 

Conference Room, rm. 1066, Rockville, 

MD 20857. 

Contact Person: Lee L. Zwanziger, 

Office of Policy, Planning and Budget, 

Food and Drug Administration, 10903 

New Hampshire Ave., Bldg. 32, rm. 

3278, Silver Spring, MD 20993–0002, 

301–796–9151, FAX: 301–847–8611, 

e-mail: RCAC@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), and follow the 

prompts to the desired center or product 

area. Please call the Information Line for 

up-to-date information on this meeting. 

A notice in the Federal Register about 

last minute modifications that impact a 

previously announced advisory 

committee meeting cannot always be 

published quickly enough to provide 

timely notice. Therefore, you should 

always check the Agency’s Web site and 

call the appropriate advisory committee 

hot line/phone line to learn about 

possible modifications before coming to 

the meeting. 

Agenda: On May 5, 2011, the 

committee will hear and discuss 

developments in FDA’s ongoing 

communications programs. The 

discussion will focus on the use of 

different channels for information 

dissemination, tracking how 

information is gathered and spread, and 

thoughts on reaching less accessible 

target audiences. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before April 29, 2011. Oral 

presentations from the public will be 

scheduled between approximately 

1 p.m. and 2 p.m. on May 5, 2011. 

Those individuals interested in making 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before April 21, 2011. Time allotted 

for each presentation may be limited. If 

the number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by April 22, 2011. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Lee L. 

Zwanziger at least 7 days in advance of 

the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act 

(5 U.S.C. app. 2). 

Dated: March 17, 2011. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2011–6788 Filed 3–22–11; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Indian Health Service 

Memorandum of Agreement Between 

the Indian Health Service and the 

Department of Interior; Bureau of 

Indian Affairs and Bureau of Indian 

Education 

AGENCY: Indian Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The Indian Health Service 

(IHS) is providing notice of a 

Memorandum of Agreement (MOA) 

between the IHS and the Department of 

the Interior (DOI), signed in 2009, and 

has developed an amendment to that 

MOA that includes language consistent 

with Section 703 of the Indian Health 

Care Improvement Act (IHCIA), Public 

Law 94–437, as amended. The purpose 

of the MOA and the amendment is to 

advance our partnership with Tribes 

and Federal stakeholders on alcohol and 

substance abuse prevention and 

treatment. The Patient Protection and 

Affordable Care Act’s, Public Law 111– 

148, permanent authorization of the 

Indian Health Care Improvement Act 

(IHCIA) establishes timelines and 

requirements for coordinated actions by 

the Department of Interior (DOI), the 

Department of Health and Human 

Services (HHS), Tribes and Tribal 

organizations. Specifically, Section 703 

of the IHCIA provides new authorities 

that permit the DOI and HHS, acting 

through the Indian Health Service (IHS), 

to develop and enter into a 

Memorandum of Agreement (MOA), or 

review and update any existing 

memoranda of agreement, as required by 

Section 4205 of the Indian Alcohol and 

Substance Abuse Prevention and 

Treatment Act of 1986 (25 U.S.C.2411). 

DOI and IHS signed an MOA on this 

topic in 2009, and have developed an 

amendment to that MOA that includes 

language consistent with the new IHCIA 

provision. In accordance with Section 

703 of the IHCIA, which states that the 

MOA between the IHS and DOI shall be 

published in the Federal Register, the 

agency is publishing notice of this MOA 

and the amendment to this MOA. 

DATES: The original MOA was effective 

on December 12, 2009. The amendment 

is effective March 1, 2011. 


jlentini on DSKJ8SOYB1PROD with NOTICES